Theralase Appoints Corporate Business Development Officer



    TORONTO, July 28 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today
announced that Mr. Mark Lemieux has been appointed the Company's Business
Development Officer to concentrate on expanding North American sales and
distribution.
    Mark Lemieux has proven experience in sales, marketing, business
development and strategic planning in large corporate environments. Mr.
Lemieux has over 22 years of sales and marketing experience as a senior
business development executive in major healthcare with firms such as Marion
Merrell Dow Canada, Warner Lambert Consumer Healthcare and Pfizer Canada
Healthcare Canada.
    "The Company is pleased that Mark has joined Theralase," said Roger
Dumoulin-White, President & CEO of Theralase Technologies Inc. "He has a
strong track record with world class companies that he can leverage to expand
our sales and marketing into the growing North American market. We look
forward to working with Mark in achieving Theralase's growth milestones."

    Theralase Technologies Inc. designs, develops and manufactures patented,
super-pulsed laser technology used in a wide range of bio-stimulation and
bio-destruction clinical applications. The Theralase technology platform
targets several diverse healthcare sectors: firstly, for non-invasive pain
management and clinical therapy, in hundreds of neural muscular skeletal
conditions, including arthritis; secondly, to bio-stimulate and accelerate
wound care and healing, including bone fracture regeneration; and thirdly,
combining photodynamic compounds with super-pulsed, biofeedback laser
technology to attack specifically targeted cancer, bacteria, viruses and fat
cells.

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of the contents of this
    release.





For further information:

For further information: Roger White, President & CEO, Toll Free:
1-866-THE-LASE (843-5273), Phone: (416) 447-8455, e-mail:
rwhite@theralase.com; Vanessa Beresford, The Equicom Group, Phone: (416)
815-0700 ext 227, e-mail: vberesford@equicomgroup.com

Organization Profile

THERALASE TECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890